Corrigendum to ‘Repeated GnRH agonist doses for luteal support: a proof of concept’ (Reproductive BioMedicine Online (2019) 39(5) (770–776), (S1472648319306649), (10.1016/j.rbmo.2019.07.031))

Amir Wiser, Anat Hershko Klement, Tal Shavit, Arie Berkovitz, Roni Rahav Koren, Ofer Gonen, Keren Amichay, Adrian Shulman

Research output: Contribution to journalComment/debate

Abstract

The authors regret that the abstract and methods were inconsistent regarding the starting day of luteal support. Both hCG and GnRH agonist were introduced by the 3rd day post egg retrieval. The corrections should be; 1. In the abstract, ‘Design’ section: ‘: randomized to GnRH agonist luteal support 0.1 mg SC every other day, starting on day 3 after egg retrieval.2. In ‘Materials and Methods’ section: The control group was supported by 80 µg recombinant hCG (Ovitrelle, Merck Serono SA, Bari, Italy). A single dose on day 3 post-egg retrieval.The following figure clarifies the treatment protocol: [Figure presented]

Original languageEnglish
Pages (from-to)343
Number of pages1
JournalReproductive BioMedicine Online
Volume40
Issue number2
DOIs
StatePublished - Feb 2020

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Repeated GnRH agonist doses for luteal support: a proof of concept’ (Reproductive BioMedicine Online (2019) 39(5) (770–776), (S1472648319306649), (10.1016/j.rbmo.2019.07.031))'. Together they form a unique fingerprint.

Cite this